Altuğ TUNCEL, Fazlı POLAT, Süleyman YEŞİL, Çağdaş ŞENEL, Ali ATAN

Ürolojik Bakış Açısından Metabolik Sendromun Önemi

Metabolik sendrom (MS), obezite, hiperglisemi-insülin direnci, hipertansiyon ve dislipidemi gibi bileşenleri olanmetabolik bir bozukluktur. Yaşam tarzındaki değişiklikler sonucunda özellikle batı ülkelerinde bu tablonun sıklığıgiderek artmış ve günümüzün önemli halk sağlığı sorunlarından biri haline gelmiştir. Uzun süre bu klinik tablonunsadece kardiyovasküler ve endokrinolojik hastalıklarla ilişkisi vurgulanmıştır. Ancak son yıllarda yapılan çalışmalardametabolik sendromun benign prostat hiperplazisi/alt üriner sistem yakınmaları, prostat kanseri, erektil disfonksiyon,erkek infertilitesi, üriner sistem taş hastalığı, üriner inkontinans gibi pek çok ürolojik hastalığın da oluşumundarol oynadığı gösterilmiş ürolojik açıdan önemi ortaya konulmuştur. Bu derlemede metabolik sendromun ürolojikhastalıkların patogenezindeki rolü ve ürolojik açıdan önemi güncel literatür ışığında özetlenmiştir.

The Importance of Metabolic Syndome In Urological Perspective

Metabolic syndrome (MS) is composed of obesity, hyperglycemia-insulin resistance, hypertension and dyslipidemia.As a result of lifestyle changes, the incidence of MS has increased especially in Western countries. MS has become animportant public health problem. For many years this disorder s cardiovascular and endocrinological relations wereemphasized. But in recent years MS is found to be related with the pathogenesis of benign prostate hyperplasia/lowerurinary tract symptoms, prostate cancer, erectile dysfunction, male infertility, urinary system stone disease, urinaryincontinence. In this review, the role of MS in the pathogenesis of urologic disorders and the importance in urologywere summarized in the light of current literature.

PDF

___

1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and me- tabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009; 94:1853-1878.
2. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol 2010; 12:157-180.
3. Brotman DJ, Girod JP. The metabolic syndrome: a tug-of-war with no winner. Cleve Clin J Med 2002; 69:990-994.
4. Ford ES, Li C. Physical activity or fitness and the metabolic syndrome. Expert Rev Cardiovasc Ther 2006; 4:897-915.
5. Gündüz MI, Gümüs BH, Sekuri C. Relationship between meta- bolic syndrome and erectile dysfunction. Asian J Androl 2004; 6:355-358.
6. Demir T, Demir O, Kefi A, Comlekci A, Yesil S, Esen A. Prevalen- ce of erectile dysfunction in patients with metabolic syndrome. Int J Urol 2006; 13:385-388.
7. Bal K, Oder M, Sahin AS, et al. Prevalence of metabolic syndro- me and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction. Urology 2007; 69:356-360.
8. Aslan Y, Sezgin T, Tuncel A, Tekdogan UY, Guler S, Atan A. Is type 2 diabetes mellitus a cause of severe erectile dysfunction in patients with metabolic syndrome? Urology 2009; 74: 561-564.
9. Chughtai B, Lee RK, Te AE, Kaplan SA. Metabolic syndrome and sexual dysfunction. Curr Opin Urol 2011; 21:514-518.
10. Lee RK, Chughtai B, Te AE, Kaplan SA. Sexual function in men with metabolic syndrome. Urol Clin North Am 2012; 39:53-62.
11. Esposito K, Giugliano F, Martedì E, et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2004; 28:1201-1203.
12. Traish AM, Feeley RJ, Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS J 2009; 276:5755-5767.
13. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Me- mis A. The correlation between metabolic syndrome and prosta- tic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199-203.
14. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004; 172:1390-1393.
15. Kupelian V, McVary KT, Kaplan SA,et al. Association of lower uri- nary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009; 182:616-624.
16. Demir O, Akgul K, Akar Z,et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009; 12:29-34. 17. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1:157-162.
18. McVary K. Lower urinary tract symptoms and sexual dysfuncti- on: epidemiology and pathophysiology. BJU Int 2006; 97 (suppl 2):23-28.
19. Ullrich PM, Lutgendorf SK, Kreder KJ. Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperpla- sia. Urology 2007; 70:487-492.
20. Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsu- linemia with benign prostate hyperplasia. Prostate 2010; 70:79-89.
21. Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol 2001; 165:1626-1635.
22. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB. Chronic ischemia increases prostatic smooth muscle contraction in the rab- bit. J Urol 2003; 170 (2 Pt 1):659-663.
23. Ho CK, Nanda J, Chapman KE, Habib FK. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and lo- cal formation from androgen. J Endocrinol 2008; 197:483-491.
24. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inf- lammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 33:475-488.
25. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkara- inen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemi- ol Biomarkers Prev 2004; 13:1646-1650.
26. Tuohimaa P, Tenkanen L, Syvälä H, et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of pros- tate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:302-307.
27. Jayachandran J, Bañez LL, Aronson WJ, et al. Obesity as a predic- tor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2009; 115:5263-5271.
28. Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, gluco- se, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009; 101:1272-1279.
29. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009; 124:1398-1403.
30. Vykhovanets EV, Shukla S, MacLennan GT,et al. Molecular ima- ging of NF-kappaB in prostate tissue after systemic administration of IL-1 beta. Prostate 2008; 68:34-41.
31. West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis 2008; 51:741-747.
32. Brown JS, Grady D, Ouslander JG, Herzog AR, Varner RE, Posner SF. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen/Progestin Repla- cement Study (HERS) Research Group. Obstet Gynecol 1999; 94:66-70.
33. Lawrence JM, Lukacz ES, Liu IL, Nager CW, Luber KM. Pel- vic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente Continence Associated Risk Epidemiology Study. Diabetes Care 2007; 30:2536-2541.
34. Zhu L, Lang J, Wang H, Han S, Huang J. The prevalence of and potential risk factors for female urinary incontinence in Beijing, China. Menopause 2008; 15:566-569.
35. Zhu L, Lang J, Liu C, Han S, Huang J, Li X. The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China. Menopause 2009; 16:831-836.
36. Bump RC, Sugerman HJ, Fantl JA, McClish DK. Obesity and lo- wer urinary tract function in women: effect of surgically induced weight loss. Am J Obstet Gynecol 1992; 167:392-397.
37. Subak LL, Wing R, West DS,et al. Weight loss to treat urinary in- continence in overweight and obese women. N Engl J Med 2009; 360:481-490.